RephImmune has been selected as a member of the Taiwan delegation for the 2024 SelectUSA Investment Summit.
Led by Ministry of Economic Affairs, AIT, Small and Medium Enterprise and Startup Administration and the TAcc+ accelerator, nineteen Taiwanese companies from various industries will travel to Washington, D.C., to attend the 10th SelectUSA Investment Summit from June 23 to 26. This summit is the premier event for promoting investment in the United States, serving as a bridge between global companies and economic development organizations across the U.S.
https://www.selectusasummit.us/
RephImmune Wins 3rd Place in Health Tech Pitching Competition at SelectUSA Investment Summit.
Rephimmune won third place in the Health Technology Competition at the SelectUSA Investment Summit held from June 23-26, 2024. The competition saw participation from 80 startups across 37 global markets. Rephimmune stood out with its revolutionary RACE-T cell therapy, which has the potential to transform cancer treatment.
This honor not only highlights Rephimmune's leading position in the field of cancer therapy research and development but also underscores its commitment to improving treatment outcomes for patients worldwide. The summit attracted applications from over 260 startups globally, making the competition extremely fierce. Rephimmune's success in such a strong field demonstrates the immense potential of its technology.
Rephimmune's achievement lays a solid foundation for future collaborations and investments. As a pioneer in cancer treatment, Rephimmune looks forward to more breakthroughs and innovations, continuing to lead the future of cancer therapy for the benefit of patients worldwide.
https://www.selectusasummit.us/Programming/SelectUSA-Tech
RephImmune has been selected as a finalist for the 2024 MassChallenge Switzerland Accelerator.
MassChallenge is renowned as one of the world's most prestigious accelerators, and Switzerland is a leading nation in biotechnology and cell & gene therapy. In 2024, MassChallenge Switzerland selected 103 startups from over 1,300 global applicants through a rigorous selection process, representing the top 8% of all applicants. As the only representative from Taiwan, RephImmune's innovative engineered cell therapy has been recognized and honored to join this esteemed group.
